Soligenix, Inc. - Common Stock (SNGX)
2.8600
-0.1800 (-5.92%)
NASDAQ · Last Trade: Sep 6th, 10:16 AM EDT
Detailed Quote
| Previous Close | 3.040 |
|---|---|
| Open | 3.070 |
| Bid | 2.850 |
| Ask | 3.010 |
| Day's Range | 2.860 - 3.070 |
| 52 Week Range | 1.090 - 6.230 |
| Volume | 234,583 |
| Market Cap | 10.02M |
| PE Ratio (TTM) | -0.7709 |
| EPS (TTM) | -3.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 9,454,281 |
Chart
About Soligenix, Inc. - Common Stock (SNGX)
Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs. The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options. Read More
News & Press Releases
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of new data showing extended stability of its ebolavirus vaccines developed with the ThermoVax(R) platform. Bivalent and trivalent vaccines formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens retained full potency after two years of storage at up to 40°C (104°F), according to a manuscript accepted by Vaccine . Developed in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, the thermostable vaccines have demonstrated robust immune responses in animal models, with up to 100% protection in non-human primates. Soligenix noted that ThermoVax enhances protein subunit vaccines—long considered the gold standard for safety—by eliminating cold-chain requirements and improving global vaccine distribution and pandemic preparedness.
Via Investor Brand Network · September 4, 2025
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease ( https://ibn.fm/0t1aK ). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing reputation as a late-stage biopharmaceutical innovator dedicated to tackling serious, underserved conditions.
Via Investor Brand Network · September 4, 2025
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8–10, 2025. The on-demand presentation will be available beginning Sept. 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event.
Via Investor Brand Network · September 2, 2025
Study Explains Why Blood Clotting is Common in IBD Patients
About 3 million people in the U.S. live with irritable bowel disease (IBD), and its prevalence is rising. Unfortunately, there isn’t a cure for the condition at the moment. Many individuals with IBD develop clots in their blood and these can result in strokes and heart attacks . Now a new study has discovered possible reasons why these clots are common and suggests a possible way to address this problem while also reducing inflammation.
Via Investor Brand Network · August 28, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year ( https://ibn.fm/1dhGj ).
Via Investor Brand Network · August 26, 2025
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
Via Benzinga · August 21, 2025
Via Benzinga · August 20, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · August 19, 2025
Via Benzinga · August 19, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · August 19, 2025
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · August 19, 2025
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · August 19, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 19, 2025
Via Benzinga · August 18, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · August 18, 2025
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · August 18, 2025
Discover the most active stocks in Monday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · August 18, 2025
Via Benzinga · August 18, 2025
Soligenix shares surge after FDA granted orphan drug designation to dusquetide for Behçet's Disease, boosting prospects for rare disease treatment.
Via Benzinga · August 18, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · August 18, 2025
Synergy CHC Corp. (NASDAQ: SNYR) is supercharging its retail expansion with a nationwide rollout of FOCUSfactor® Focus + Energy through EG America, the 6th largest U.S. convenience chain . The deal instantly places the functional brain health beverage in 1,600+ high-traffic locations , including Cumberland Farms, Turkey Hill, Tom Thumb (Albertsons Companies Inc. – NYSE: ACI), Loaf ’N Jug, and Minit Mart .
Via AB Newswire · August 18, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · August 18, 2025
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the U.S. FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treatment of Behçet’s Disease. The designation follows a review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients.
Via Investor Brand Network · August 18, 2025